Pancreatic Cancer

John Neoptolemos is Professor of Surgery and Head of the Division of Surgery and Oncology at the University of Liverpool and Honorary Consultant Surgeon at the Royal Liverpool University Hospital. As an undergraduate he studied Natural Sciences at Cambridge (BA 1973, MA 1976) before completing his clinical undergraduate training at Guys Hospital (Cambridge: MB, BChir 1976). He completed his academic and clinical training in Leicester under Prof. Sir Peter Bell, being awarded a Doctorate in Medicine in 1986.
Raul A. Urrutia, M.D., Mayo Clinic College of Medicine, Rochester, MN USA. Dr. Urrutia was awarded his M.D., Magna Cum Laude, by the University of Cordoba, Argentina.
Dr. James L. Abbruzzese is the Chairman of the Department of Gastrointestinal Medical Oncology at the University of Texas M. D. Anderson Cancer Center, Houston, Texas, where he holds the Annie Laurie Howard Research Distinguished Professorship. Author of over 150 original articles and book chapters, Dr. Abbruzzese has recently been appointed the Editor-in-Chief of the International Journal of Pancreatology. He serves on the editorial board of a number of prestigious journals, including the Journal of Clinical Oncology and Clinical Cancer Research, and also serves on the Scientific Advisory Board of the Lustgarten Foundation for Pancreatic Cancer Research.
Markus W. Büchler is Professor of Surgery at the University of Heidelberg, Germany. He studied medicine at the Universities of Heidelberg and Berlin and was trained in surgery at the Department of Surgery, University of Ulm, where he was appointed a Consultant Surgeon in 1987 and Vice Chairman in 1991. Professor Büchler is a specialist in hepato-pancreato-biliary surgery (HPB) and, in particular, pancreatic surgery. He has a substantial curriculum of scientific publications in the field of HPB diseases, especially in translational research of pancreatic cancer. He is Editor or Editorial Board member of many leading journals in general and gastrointestinal surgery, translational and molecular research in pancreatology and other gastrointestinal diseases, including Annals of Surgery, British Journal of Surgery. Digestive Surgery (Editor), Pancreas, Langenbeck's Archive of Surgery (Editor), HPB, and Surgery.

Worldwide, there are an estimated 232, 000 new cases of pancreatic cancer annually. In the United States, it is the fourth leading cause of cancer death, and approximately 30,000 people die of pancreatic cancer each year. The disease is difficult to diagnose in its early stages, and most patients have incurable disease by the time they present with symptoms. The overall 5-year survival rate for this disease is less than 5%.
In organizing this handbook, Dr. Neoptolemos and his co-editors will produce a distinguished Major Reference Work devoted to pancreatic cancer. This handbook will have widespread appeal among clinicians, pathologists and basic scientists who are now struggling to understand this complex and rapidly expanding field.
Because of the recent and vast growth in both the clinical and scientific research being done in pancreatic cancer (there is currently an unprecedented investment by academia and industry in this field), each researcher s knowledge of other specialty areas outside his or her own is now often quite limited. The aim of this book is to place these the tangible advances those that are indispensable to all working on pancreatic cancer readily at hand. The book will focus on advances that will not become dated, and the editors will choose authors who are the very best in each area.

This handbook details advances in pancreatic cancer research that have a profound and lasting impact on the field. It features the work of authors who are the very best in their respective fields and will have widespread appeal among clinicians, pathologists and basic scientists who are now struggling to understand this complex and rapidly expanding field.

This handbook details advances in pancreatic cancer research that have a profound and lasting impact on the field. It features the work of authors who are the very best in their respective fields and will have widespread appeal among clinicians, pathologists and basic scientists who are now struggling to understand this complex and rapidly expanding field.

Epidemiology: world overview, risk factors, prospects for prevention.- Development and structure of pancreas.- Pathologic classification and biological behaviour of pancreatic neoplasia.- Developmental molecular biology of the pancreas.- Molecular pathology of precursor lesions of pancreatic cancer, pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), and mucinous cystic neoplasm (MCN).- Epigenetics: its fundamentals and applications to a revised comprehensive progression model for pancreatic cancer.- Molecular pathology of pancreatic neuroendocrine tumours MEN-1: gastrinomas, insulinoma, Non-Functioning Tumours, VIPoma, glucagonoma, Von Hippel-Lindau, Neurofibromatosis.- Sporadic neuroendocrine pancreatic tumours.- Molecular pathology of non-pancreatic cancer lesions: Ampullary cancer, intra-pancreatic bile duct cancer, and duodenal cancer.- Miscellaneous non-pancreatic non-endocrine tumours.- Novel molecular relationships between chronic pancreatitis and cancer.- Pancreatic cancer stem cells.- Cell cycle control: signalling pathways in pancreatic pathogenesis.- Apoptosis: signalling pathways in pancreatic pathogenesis.- EGFR: signalling pathways in pancreatic pathogenesis Pl3, Akt, lKK, Ras, Raf, MAPKK, ERK.- Hedgehog: signalling pathways in pancreatic pathogenesis.- Smad4/TGF-ß pathway: signalling pathways in pancreatic pathogenesis.- Notch signalling in pancreatic morphogenesis and pancreatic cancer.- Molecular characterization of pancreatic cell lines.- Mouse models of exocrine pancreatic cancer.- Principles and applications of microarray gene expression in pancreatic cancer.- Principles and applications of proteomics in pancreatic cancer.- Tumour-stromal interaction: invasion and metastases.- Genetic susceptibility, high risk groups, chronic and hereditary pancreatitis, familial pancreatic cancer syndromes.- Inherited endocrine pancreatic tumors associated with Multiple Endocrine Neoplasia Type 1 Von-Hippel-Lindau Syndrome, and Neurofibromatosis Type 1.- Clinical decision making in pancreatic cancer.- Paraneoplastic syndromes.- Diagnostic and therapeutic response markers.- CT and fusion PET-CT Diagnosis, staging, and follow-up.- MRI and MRCP: diagnosis and staging of pancreatic cancer.- EUS Diagnosis and staging.- Laparoscopy and laparoscopic ultrasound: diagnosis and staging.- Overview of palliative management for pancreatic cancer.- Endoscopy.- Interventional radiology.- Role of palliative surgery in advanced pancreatic cancer.- Chemotherapy for advanced pancreatic cancer.- Developments in chemoradiation in advanced pancreatic cancer.- Surgical resection for pancreatic cancer.- Role of venous resection in pancreatic cancer surgery.- Pathological reporting and staging following resection.- Japanese Pancreas Society staging for pancreatic cancer.- Adjuvant chemotherapy in pancreatic cancer.- Case for adjuvant chemoradiation therapy for pancreatic cancer.- Case for neoadjuvant treatment in pancreatic cancer.- Borderline resectable disease.- Management of cystic neoplasms serous cystic neoplasms mucinous, cystic neoplasms, intraductal paillary mucinous neoplasms.- Laparoscopic surgery for pancreatic neoplasm.- Modern Japanese approach to pancreas cancer.- Development of novel biomarkers.- Inherited genetics of pancreatic cancer and secondary screening.- Gene therapy for pancreatic cancer.- Vaccine therapy and immunotherapy.- Emerging targets in pancreatic cancer.-